161 related articles for article (PubMed ID: 15872183)
21. Cancer-specific induction of adenoviral E1A expression by group I intron-based trans-splicing ribozyme.
Won YS; Lee SW
J Microbiol Biotechnol; 2012 Mar; 22(3):431-5. PubMed ID: 22450801
[TBL] [Abstract][Full Text] [Related]
22. Optimizing the substrate specificity of a group I intron ribozyme.
Zarrinkar PP; Sullenger BA
Biochemistry; 1999 Mar; 38(11):3426-32. PubMed ID: 10079089
[TBL] [Abstract][Full Text] [Related]
23. Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding.
Trang P; Hsu A; Zhou T; Lee J; Kilani AF; Nepomuceno E; Liu F
J Mol Biol; 2002 Jan; 315(4):573-86. PubMed ID: 11812131
[TBL] [Abstract][Full Text] [Related]
24. Gene expression responses in vivo by human telomerase reverse transcriptase (hTERT)-targeting trans-splicing ribozyme.
Song MS; Jeong JS; Cho KS; Lee SW
Exp Mol Med; 2007 Dec; 39(6):722-32. PubMed ID: 18160843
[TBL] [Abstract][Full Text] [Related]
25. Optimization and application of the group I ribozyme trans-splicing reaction.
Einvik C; Fiskaa T; Lundblad EW; Johansen S
Methods Mol Biol; 2004; 252():359-71. PubMed ID: 15017063
[TBL] [Abstract][Full Text] [Related]
26. Heterodimerization of Group I Ribozymes Enabling Exon Recombination through Pairs of Cooperative trans-Splicing Reactions.
Tanaka T; Hirata Y; Tominaga Y; Furuta H; Matsumura S; Ikawa Y
Chembiochem; 2017 Aug; 18(16):1659-1667. PubMed ID: 28556398
[TBL] [Abstract][Full Text] [Related]
27. Evaluating group I intron catalytic efficiency in mammalian cells.
Long MB; Sullenger BA
Mol Cell Biol; 1999 Oct; 19(10):6479-87. PubMed ID: 10490588
[TBL] [Abstract][Full Text] [Related]
28. Activation of the catalytic core of a group I intron by a remote 3' splice junction.
Michel F; Jaeger L; Westhof E; Kuras R; Tihy F; Xu MQ; Shub DA
Genes Dev; 1992 Aug; 6(8):1373-85. PubMed ID: 1644285
[TBL] [Abstract][Full Text] [Related]
29. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
Phylactou LA; Tsipouras P; Kilpatrick MW
Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
[TBL] [Abstract][Full Text] [Related]
30. Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript.
Kwon BS; Jung HS; Song MS; Cho KS; Kim SC; Kimm K; Jeong JS; Kim IH; Lee SW
Mol Ther; 2005 Nov; 12(5):824-34. PubMed ID: 16040278
[TBL] [Abstract][Full Text] [Related]
31. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
[TBL] [Abstract][Full Text] [Related]
32. Single-cell detection of trans-splicing ribozyme in vivo activity.
Hasegawa S; Choi JW; Rao J
J Am Chem Soc; 2004 Jun; 126(23):7158-9. PubMed ID: 15186136
[TBL] [Abstract][Full Text] [Related]
33. Kinetic characterization of the first step of the ribozyme-catalyzed trans excision-splicing reaction.
Dotson PP; Sinha J; Testa SM
FEBS J; 2008 Jun; 275(12):3110-22. PubMed ID: 18479464
[TBL] [Abstract][Full Text] [Related]
34. Antitumor effects of systemically delivered adenovirus harboring trans-splicing ribozyme in intrahepatic colon cancer mouse model.
Jeong JS; Lee SW; Hong SH; Lee YJ; Jung HI; Cho KS; Seo HH; Lee SJ; Park S; Song MS; Kim CM; Kim IH
Clin Cancer Res; 2008 Jan; 14(1):281-90. PubMed ID: 18172280
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of RNA chaperone activity in vivo and in vitro using misfolded group I ribozymes.
Semrad K
Methods Mol Biol; 2014; 1086():239-54. PubMed ID: 24136608
[TBL] [Abstract][Full Text] [Related]
36. Tumor-specific gene delivery using RNA-targeting Tetrahymena group I intron.
Jung HS; Kwon BS; Lee SW
Biotechnol Lett; 2005 Apr; 27(8):567-74. PubMed ID: 15973491
[TBL] [Abstract][Full Text] [Related]
37. RNA reprogramming and repair based on trans-splicing group I ribozymes.
Fiskaa T; Birgisdottir AB
N Biotechnol; 2010 Jul; 27(3):194-203. PubMed ID: 20219714
[TBL] [Abstract][Full Text] [Related]
38. Ribozyme mediated trans insertion-splicing of modified oligonucleotides into RNA.
Dotson PP; Frommeyer KN; Testa SM
Arch Biochem Biophys; 2008 Oct; 478(1):81-4. PubMed ID: 18671935
[TBL] [Abstract][Full Text] [Related]
39. RNA as a drug target: recent patents on the catalytic activity of trans-splicing ribozymes derived from group I intron RNA.
Johnson IM
Recent Pat DNA Gene Seq; 2010 Jan; 4(1):17-28. PubMed ID: 20218956
[TBL] [Abstract][Full Text] [Related]
40. Molecular imaging of endogenous mRNA expression in a mouse tumor model by adenovirus harboring trans-splicing ribozyme.
Hong SH; Jeong JS; Lee YJ; Jung HI; Kim KT; Kim YH; Lee YS; Lee SW; Bae CD; Park J; Kim IH
FEBS Lett; 2007 Nov; 581(28):5396-400. PubMed ID: 17976379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
